AG-0029 / Angita Pharma - LARVOL DELTA

Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D and Histamine H Receptors: A PET Study in Healthy Rats. (PubMed, Mol Pharm) - " Target engagement of AG-0029 as an agonist at dopamine D/D receptors and an antagonist at histamine H receptors could be demonstrated in the rat brain with [C]raclopride and [C]GSK-189254 PET, respectively. The measured occupancy values reflect the previously reported high (subnanomolar) affinity of AG-0029 to D/D and moderate (submicromolar) affinity to H receptors."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease